116 related articles for article (PubMed ID: 36722413)
1. Treatment patterns and long-term survival outcomes for patients with stage III non-small cell lung cancer: A retrospective study.
Kumari S; Karikios D; Yeghiaian-Alvandi R; Flynn P; Morgan L; Kay L; Ding P
Asia Pac J Clin Oncol; 2024 Feb; 20(1):25-31. PubMed ID: 36722413
[TBL] [Abstract][Full Text] [Related]
2. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
[TBL] [Abstract][Full Text] [Related]
4. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
6. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
8. [Value of surgery for stage IIIa non-small cell lung cancer].
Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
[TBL] [Abstract][Full Text] [Related]
9. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
[TBL] [Abstract][Full Text] [Related]
10. Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study.
Jazieh AR; Onal HC; Tan DSW; Soo RA; Prabhash K; Kumar A; Huggenberger R; Robb S; Cho BC
J Thorac Oncol; 2021 Oct; 16(10):1733-1744. PubMed ID: 34051381
[TBL] [Abstract][Full Text] [Related]
11. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2020 Aug; 146():112-119. PubMed ID: 32526601
[TBL] [Abstract][Full Text] [Related]
12. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
[TBL] [Abstract][Full Text] [Related]
13. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer.
Sakin A; Sahin S; Atci MM; Sakin A; Yasar N; Geredeli C; Aksaray F; Cihan S
Pulmonology; 2021; 27(1):26-34. PubMed ID: 31839507
[TBL] [Abstract][Full Text] [Related]
14. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
15. Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa - KINDLE Study.
Jazieh AR; Sağlam EK; Önal HC; Abdelkader Y; Gaafar R; Dawoud E; Nassar M; Alshorbagy D; El Ashry H; Elsayed M
Clin Lung Cancer; 2022 Jun; 23(4):364-373. PubMed ID: 35277345
[TBL] [Abstract][Full Text] [Related]
16. Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy.
Choi HS; Jeong BK; Jeong H; Lee YH; Ha IB; Song JH; Kang KM
Radiat Oncol; 2017 Jul; 12(1):122. PubMed ID: 28732516
[TBL] [Abstract][Full Text] [Related]
17. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.
Zhou Q; Chen M; Jiang O; Pan Y; Hu D; Lin Q; Wu G; Cui J; Chang J; Cheng Y; Huang C; Liu A; Yang N; Gong Y; Zhu C; Ma Z; Fang J; Chen G; Zhao J; Shi A; Lin Y; Li G; Liu Y; Wang D; Wu R; Xu X; Shi J; Liu Z; Cui N; Wang J; Wang Q; Zhang R; Yang J; Wu YL
Lancet Oncol; 2022 Feb; 23(2):209-219. PubMed ID: 35038429
[TBL] [Abstract][Full Text] [Related]
18. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
19. Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer.
Katsui K; Ogata T; Watanabe K; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Acta Med Okayama; 2021 Jun; 75(3):269-277. PubMed ID: 34176930
[TBL] [Abstract][Full Text] [Related]
20. Population-based Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients: A Real-world Evidence Study.
Yusuf D; Walton RN; Hurry M; Farrer C; Bebb DG; Cheung WY
Am J Clin Oncol; 2020 Sep; 43(9):615-620. PubMed ID: 32889830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
